首页 » 文章 » 文章详细信息
Case Reports in Endocrinology Volume 2019 ,2019-09-22
Abnormally Elevated Follicle-Stimulating Hormone (FSH) Level in an Infertile Woman
Case Report
Aurore Catteau 1 Kalyane Bach-Ngohou 1 , 2 Justine Blin 1 , 2 Paul Barrière 2 , 3 Thomas Fréour 2 , 3 Damien Masson 1 , 2
Show affiliations
DOI:10.1155/2019/3071649
Received 2019-06-17, accepted for publication 2019-08-9, Published 2019-08-9
PDF
摘要

We report a case of 33-year-old woman with a 4-year primary infertility. A high isolated follicle-stimulating hormone (FSH) level was conflicting with the clinical situation and with other hormonal markers which were in favor of polycystic ovarian syndrome. We followed a strategy used to identify immune complexes involving FSH. The PEG precipitation test revealed that the high FSH level was almost exclusively due to the presence of autoimmune FSH immunoglobulin complex (macro-FSH). The profile obtained by gel filtration chromatography confirmed the presence of an FSH-immunoglobulin complex. Such immunological dysregulation could be explored in cases of unexplained infertility and recurrent IVF failure.

授权许可

Copyright © 2019 Aurore Catteau et al. 2019
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

Damien Masson.Laboratoire de biochimie, Institut de Biologie, CHU de Nantes, Nantes, France, chu-nantes.fr;Faculté de médecine, Université de Nantes, Nantes, France, univ-nantes.fr.damien.masson@chu-nantes.fr

推荐引用方式

Aurore Catteau,Kalyane Bach-Ngohou,Justine Blin,Paul Barrière,Thomas Fréour,Damien Masson. Abnormally Elevated Follicle-Stimulating Hormone (FSH) Level in an Infertile Woman. Case Reports in Endocrinology ,Vol.2019(2019)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] H. Cappy, P. Pigny, M. Leroy-Billiard, D. Dewailly. et al.(2013). Falsely elevated serum antimüllerian hormone level in a context of heterophilic interference. Fertility and Sterility.99(6):1729-1732. DOI: 10.1016/j.ejogrb.2009.05.008.
[2] M. N. Fahie-Wilson, R. John, A. R. Ellis. (2005). Macroprolactin; high molecular mass forms of circulating prolactin. Annals of Clinical Biochemistry.42(3):175-192. DOI: 10.1016/j.ejogrb.2009.05.008.
[3] B. Gobert, C. Jolivet-Reynaud, P. Dalbon, P. Barbarino-Monnier. et al.(2001). An immunoreactive peptide of the FSH involved in autoimmune infertility. Biochemical and Biophysical Research Communications.289(4):819-824. DOI: 10.1016/j.ejogrb.2009.05.008.
[4] L. Katznelson, J. M. Alexander, H. A. Bikkal, J. L. Jameson. et al.(1992). Imbalanced follicle-stimulating hormone beta-subunit hormone biosynthesis in human pituitary adenomas. The Journal of Clinical Endocrinology and Metabolim.74(6):1343-1351. DOI: 10.1016/j.ejogrb.2009.05.008.
[5] K. Haller, A. Salumets, M. Grigorova, I. Talja. et al.(2007). Putative predictors of antibodies against follicle-stimulating hormone in female infertility: a study based on in vitro fertilization patients. American Journal of Reproductive Immunology.57(3):193-200. DOI: 10.1016/j.ejogrb.2009.05.008.
[6] E. García-González, M. Aramendía, D. Álvarez-Ballano, P. Trincado. et al.(2016). Serum sample containing endogenous antibodies interfering with multiple hormone immunoassays. Laboratory strategies to detect interference. Practical Laboratory Medicine.4:1-10. DOI: 10.1016/j.ejogrb.2009.05.008.
[7] T. Forges, P. Monnier-Barbarino, F. Guillet-May, G. C. Faure. et al.(2006). Corticosteroids in patients with antiovarian antibodies undergoing in vitro fertilization: a prospective pilot study. European Journal of Clinical Pharmacology.62(9):699-705. DOI: 10.1016/j.ejogrb.2009.05.008.
[8] K. M. Fox, J. A. Dias, P. Van Roey. (2001). Three-dimensional structure of human follicle-stimulating hormone. Molecular Endocrinology.15(3):378-389. DOI: 10.1016/j.ejogrb.2009.05.008.
[9] W. S. Vitek, O. Galárraga, P. C. Klatsky, J. C. Robins. et al.(2013). Management of the first in vitro fertilization cycle for unexplained infertility: a cost-effectiveness analysis of split in vitro fertilization-intracytoplasmic sperm injection. Fertility and Sterility.100(5):1381-1388. DOI: 10.1016/j.ejogrb.2009.05.008.
[10] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction.19(1):41-47. DOI: 10.1016/j.ejogrb.2009.05.008.
[11] A. Busnelli, A. Paffoni, L. Fedele, E. Somigliana. et al.(2016). The impact of thyroid autoimmunity on IVF/ICSI outcome: a systematic review and meta-analysis. Human Reproduction Update.22(6):793-794. DOI: 10.1016/j.ejogrb.2009.05.008.
[12] K. Haller-Kikkatalo, A. Salumets, R. Uibo. (2012). Review on autoimmune reactions in female infertility: antibodies to follicle stimulating hormone. Clinical and Developmental Immunology.2012-15. DOI: 10.1016/j.ejogrb.2009.05.008.
[13] M. P. Lauritsen, J. G. Bentzen, A. Pinborg, A. Loft. et al.(2014). The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Human Reproduction.29(4):791-801. DOI: 10.1016/j.ejogrb.2009.05.008.
[14] V. Muller, K. Ob’edkova, I. Krikheli, I. Kogan. et al.(2016). Successful pregnancy outcome in women with recurrent IVF failure and anti-hCG autoimmunity: a report of three cases. Case Reports in Immunology.2016-5. DOI: 10.1016/j.ejogrb.2009.05.008.
[15] R. Webster, M. Fahie-Wilson, P. Barker, V. K. Chatterjee. et al.(2010). Immunoglobulin interference in serum follicle-stimulating hormone assays: autoimmune and heterophilic antibody interference. Annals of Clinical Biochemistry.47(4):386-389. DOI: 10.1016/j.ejogrb.2009.05.008.
[16] P. Pigny, E. Gorisse, A. Ghulam, G. Robin. et al.(2016). Comparative assessment of five serum antimüllerian hormone assays for the diagnosis of polycystic ovary syndrome. Fertility and Sterility.105(4):1063-1069. DOI: 10.1016/j.ejogrb.2009.05.008.
[17] S. Christin-Maitre, R. Braham. (2008). General mechanisms of premature ovarian failure and clinical check-up. Gynecology Obstetrics and Fertility.36(9):857-861. DOI: 10.1016/j.ejogrb.2009.05.008.
[18] N. Gleicher, A. Weghofer, D. H. Barad. (2012). Cutting edge assessment of the impact of autoimmunity on female reproductive success. Journal of Autoimmunity.38(2–3):J74-J80. DOI: 10.1016/j.ejogrb.2009.05.008.
[19] T. Forges, P. Monnier-Barbarino, G. C. Faure, M. C. Béné. et al.(2004). Autoimmunity and antigenic targets in ovarian pathology. Human Reproduction Update.10(2):163-175. DOI: 10.1016/j.ejogrb.2009.05.008.
[20] L. Beltran, M. N. Fahie-Wilson, T. J. McKenna, L. Kavanagh. et al.(2008). Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clinical Chemistry.54(10):1673-1681. DOI: 10.1016/j.ejogrb.2009.05.008.
[21] E. S. Sills, M. M. Alper, A. P. H. Walsh. (2009). Ovarian reserve screening in infertility: practical applications and theoretical directions for research. European Journal of Obstetrics and Gynecology and Reproductive Biology.146(1):30-36. DOI: 10.1016/j.ejogrb.2009.05.008.
[22] A. Badawy, A. Elnashar. (2011). Treatment options for polycystic ovary syndrome. International Journal of Women’s Health.3:25-35. DOI: 10.1016/j.ejogrb.2009.05.008.
文献评价指标
浏览 20次
下载全文 0次
评分次数 0次
用户评分 0.0分
分享 0次